Preview

Rheumatology Science and Practice

Advanced search

THE EXPERIENCE OF REMICADE USAGE IN THE TREATMENT OF RHEUMATOID ARTHRITIS PTS

https://doi.org/10.14412/1995-4484-2002-1207

Abstract

A bstract. Objective. To study the efficacy and tolerability of Remicade in RA Material and methods. 20 reliable RA pts compatible to criteria for inclusion into the study and without exclusion criteria. 18 women and 2 men aged 30-60 and older wilh disease term from 3 lo 10 years and longer. In 14 pts RA activity was of 2" J and in 6 pts оГ 3d degree. All pts long period to the beginning of the study had methotrexate in dosage of 7.5-10 mg/week and NSAID, 4 pts had metipred 4-8 mg/day. Remicade was administrated i.v. in droplet in dosage 3 ml/kg of body weight per 250.0 ml of physiological solution lor 2 hours in 0.2, 6, 8 weeks (total 9 infusions for 54 weeks). Results. Full course of Remicade therapy on the background of methotrexate was carried out in 19 pts. All pts demonstrated speedy (after I м infusion) positive effect as reliable decrease of the number of inflamed joints, period of morning stiffness and ESR. Results of 54-weck course assessed as «excellent» in 9, «good» in 8 and «satisfactory» in 2 pts. In 6 cases remission was observed. Remicade tolerabilily was satisfactory. Only in 1 pts during the 7"' infusion bronchospasm and attack Quincke’s oedema she was excluded from further study. Transient hypotension was noticed in 2 pts. In 3 cases infection exacerbation developed (otitis, pneumonia) which required antibiotics use.

References

1. <div><p>Elliott M.J., Maini R.N., Feldmann М., el al. Randomised double-blind comparison of chimcric monoclonal antibody to tumour necrosis factor alpha (TNF</p><p>Feldmann М., Brennan F.M. Maini R.N. Role of cytokines in rheumatoid arthritis. Ann. Rev. Immunol., 1996, 14, 397 - 440.</p><p>Hanauer S.B. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther., 1999, 13, 16- 22.</p><p>Lipslcy P.E., van der Heijde D.M.F.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anli-Tumor Necrosis Factor Triul in Rheumatoid Arthritis wilh Concomitant Therapy Study Group. N Engl J Med., 2000, 343, 1594-1602.</p><p>Maini R., St Clair E.W., Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant meth- ouexate: a randomised phase III trial. Lancet, 19У9, 354, 1932 - 1939.</p><p>Markham A., Lamb H.M. Infliximab. Arcview оГ its use in the management of rheumatoid arthrolis II Drugs. - 2000. - Vol. 59. - P. 1341 - 1359.</p><p>Moreland L.W., Baumgartner S.W., Schiff M.H., et al.Treatment of rheumatoid arthritis with a recombinunt human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997, 337, 141-147.</p><p>Updated consensus statement on tumor nccrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001) // Ann. Rheum. Dis. 2001. 60. 2- 5.</p></div><br />


Review

For citations:


Soroka N.F., Grigorchuk I.P., Alikevich I.N. THE EXPERIENCE OF REMICADE USAGE IN THE TREATMENT OF RHEUMATOID ARTHRITIS PTS. Rheumatology Science and Practice. 2002;40(3):4-7. (In Russ.) https://doi.org/10.14412/1995-4484-2002-1207

Views: 1551


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)